thiorphan has been researched along with Alloxan Diabetes in 7 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Renoprotective potential of thiorphan (NEPi)/telmisartan (ARB) and thiorphan/Dize (ACE2 activator) combination therapies against the development of DN is primarily attributed to normalisation of RAS and NPS components and inhibition of pathological signalling related to inflammation, fibrosis, and apoptosis." | 3.91 | Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. ( Gaikwad, AB; Malek, V; Sankrityayan, H; Sharma, N, 2019) |
| " The dose-response curve for ET-1 was shifted to the left in the diabetics, so that at some lower doses of ET-1 the vasoconstriction was greater than in the controls." | 1.36 | Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. ( Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y; Taguchi, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, V | 3 |
| Sharma, N | 2 |
| Gaikwad, AB | 3 |
| Sankrityayan, H | 1 |
| Prasad, T | 1 |
| Roksnoer, LC | 1 |
| Zhu, P | 1 |
| Verma, A | 1 |
| Li, Y | 1 |
| Batenburg, WW | 1 |
| de Vries, R | 1 |
| Danser, AH | 1 |
| Li, Q | 1 |
| Matsumoto, T | 1 |
| Ozawa, Y | 1 |
| Taguchi, K | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Chakir, M | 1 |
| D'Orléans-Juste, P | 1 |
| Plante, GE | 1 |
| Arbin, V | 1 |
| Claperon, N | 1 |
| Fournié-Zaluski, MC | 1 |
| Roques, BP | 1 |
| Peyroux, J | 1 |
7 other studies available for thiorphan and Alloxan Diabetes
| Article | Year |
|---|---|
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
Topics: Angiotensin-Converting Enzyme 2; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1 | 2019 |
Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy.
Topics: Acetylation; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experim | 2019 |
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephr | 2019 |
Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Diabetes Me | 2016 |
Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
Topics: Animals; Aspartic Acid Endopeptidases; Benzofurans; Blood Glucose; Body Weight; Coronary Vessels; Di | 2010 |
Neutral endopeptidase inhibition, a new approach in the exploration of diabetic vasculopathy in rats.
Topics: Alanine; Animals; Blood Pressure; Capillary Permeability; Captopril; Diabetes Mellitus, Experimental | 1995 |
Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.
Topics: 3-Mercaptopropionic Acid; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Flow Velocity; Bl | 2000 |